ERBB2 and aneurysmal bone cyst: The probability sensitivity analysis using the cost-effectiveness acceptability curve (Figure 2) and scatter plot (Supplementary Figure S3) revealed that the probability of T-DXd being the dominant strategy is about 1.5%, 0.5%, and 28.0% in overall, HR+, and HR- HER2-low ABC patients, respectively, at the WTP of 150,000/QALY.